| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5549507 | Synergy | 2017 | 5 Pages |
Abstract
At the conclusion of all drug research is the 'approval of the (new) drug'. Therefore, for scientists, it's unavoidable to think about the process of regulation. First, keep in mind that all regulators are (very) conservative. All regulators have learned the lesson: avoid pharmacovigilance cases. Don't take risks; it will infringe on your career. Non-approval is the best way to avoid failures. To be frank, there were and are several unacceptable combinations on the market. If new ideas like 'synergy' come up, 'slow motion' is the state-of-the-art response among regulators. But, maybe there's light at the end of the tunnel.
Graphical abstractDownload high-res image (183KB)Download full-size image
Related Topics
Health Sciences
Medicine and Dentistry
Medicine and Dentistry (General)
Authors
H.G Schweim,